Cryoport stock trades near its 52-week high after revenue beat

Cryoport stock trades near its 52-week high after the company reported Q2 2026 revenue of USD 48.97 million. On September 23, 2026, the Nasdaq-listed shares stood at USD 17.49, down 0.46 percent from the previous close and 2.02 percent below the USD 17.85 yearly high.

Q2 revenue beat estimates

Cryoport's second-quarter revenue exceeded the USD 48.18 million consensus estimate by USD 0.79 million, according to MarketBeat. The result was published for the quarter ended June 30, 2026, giving the company a sales figure above expectations while the earnings result remained weaker than forecast.

The adjusted EPS loss was USD 0.20 versus a consensus loss of USD 0.19, a miss of USD 0.01, the same MarketBeat report states. Cryoport therefore combines a revenue beat with an ongoing profitability challenge, making the gap between sales execution and earnings conversion the key operating detail.

Analyst targets exceed the quote

BTIG Research reiterated a Buy rating and set a USD 25 price target on September 18, 2026, according to MarketBeat. That target is USD 7.51 above the September 23 quote, while the broader analyst consensus was Moderate Buy with an average target of USD 18.00. The dispersion matters because the average target sits only USD 0.51 above the market price, whereas the BTIG view is materially higher.

Stock remains near yearly high

Cryoport's market capitalization was USD 881,536,454 on September 23, 2026. The company operates temperature-controlled logistics and supply-chain services for biopharmaceutical, animal health and reproductive medicine customers, linking the stock's valuation to both recent revenue delivery and the pace of a return to profitability.